This study is a prospective, observational multicentric study. The study population entails adult patients hospitalized with a high clinical suspicion of COVID-19 and consists of two study arms (SARS-CoV2- vs. SARS-CoV2+).This combined fundamental research project has a dual goal: on the one hand assessing immunological predisposing factors for severe infection and investigating the immunological impact of SARS-CoV2 infection, on the other hand studying viral characteristics. Furthermore, a substudy will examine the pharmacokinetics and pharmacodynamics of hydroxychloroquine in patients receiving this antiviral treatment (REVIVE susbstudy). To answer these research questions, samples will be collected from patients with a high clinical suspicion of COVID-19, hospitalized at UZ Gent and 2 participating hospitals in Ghent (AZ Maria Middelares en AZ Jan Palfijn).
Not Provided
Procedure: Blood draw
8x9mL EDTA tubes. In subjects treated with hydroxychloroquine treatment an extra EDTA tube (4mL) will be collected for the REVIVE substudy.
Procedure: Bronchoalveolar lavage
Only in case of diagnostic or therapeutic indication.
Procedure: SARS CoV-2 swabs
Nasopharyngeal, oropharyngeal and nasal swabs
Inclusion Criteria:
- Upper or lower respiratory symptoms and temperature ≥37.5°C, with high clinical
suspicion of COVID-19
- Requiring hospitalization
Exclusion Criteria:
- Known pregnancy at the time of screening
- Inability to give informed consent or absence of legal representative who can give
informed consent.
AZ Jan Palfijn
Gent, Oost-Vlaanderen, Belgium
AZ Maria Middelares
Gent, Oost-Vlaanderen, Belgium
UZ Gent
Gent, Oost-Vlaanderen, Belgium
Linos Vandekerckhove, Prof. MD, Principal Investigator
University Hospital, Ghent